BTIG Research Lowers Teva Pharmaceutical Industries (NYSE:TEVA) to Neutral

BTIG Research cut shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a buy rating to a neutral rating in a research note issued to investors on Thursday, January 18th, Marketbeat.com reports. The brokerage currently has $24.00 price target on the stock. The analysts noted that the move was a valuation call.

Several other research firms have also issued reports on TEVA. ValuEngine raised Teva Pharmaceutical Industries from a buy rating to a strong-buy rating in a research report on Thursday, January 11th. Vetr lowered Teva Pharmaceutical Industries from a strong-buy rating to a buy rating and set a $22.63 price target on the stock. in a research report on Thursday, January 11th. Zacks Investment Research lowered Teva Pharmaceutical Industries from a hold rating to a sell rating in a research report on Friday, January 12th. Goldman Sachs Group upped their price target on Teva Pharmaceutical Industries from $20.00 to $25.00 and gave the company a buy rating in a research report on Thursday, January 11th. Finally, Wells Fargo & Co lowered Teva Pharmaceutical Industries from a market perform rating to an underperform rating and dropped their price target for the company from $19.58 to $17.00 in a research report on Friday, January 5th. Ten investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and seven have given a buy rating to the company. Teva Pharmaceutical Industries has an average rating of Hold and an average price target of $21.26.

Shares of Teva Pharmaceutical Industries (NYSE TEVA) traded up $0.66 on Thursday, hitting $19.27. The company’s stock had a trading volume of 16,653,803 shares, compared to its average volume of 19,710,000. Teva Pharmaceutical Industries has a one year low of $10.85 and a one year high of $37.94. The firm has a market cap of $20,020.00, a price-to-earnings ratio of -1.19, a price-to-earnings-growth ratio of 1.37 and a beta of 0.59. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Thursday, February 8th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.77 by $0.14. Teva Pharmaceutical Industries had a positive return on equity of 14.52% and a negative net margin of 72.66%. The company had revenue of $5.46 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period in the prior year, the company posted $1.38 EPS. Teva Pharmaceutical Industries’s quarterly revenue was down 15.9% on a year-over-year basis. analysts anticipate that Teva Pharmaceutical Industries will post 2.73 earnings per share for the current year.

Several large investors have recently added to or reduced their stakes in TEVA. Schwab Charles Investment Management Inc. grew its stake in shares of Teva Pharmaceutical Industries by 7.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 241,571 shares of the company’s stock worth $8,025,000 after purchasing an additional 17,116 shares in the last quarter. Prudential Financial Inc. grew its stake in shares of Teva Pharmaceutical Industries by 0.9% in the second quarter. Prudential Financial Inc. now owns 77,973 shares of the company’s stock worth $2,590,000 after purchasing an additional 730 shares in the last quarter. Principal Financial Group Inc. grew its stake in shares of Teva Pharmaceutical Industries by 21.1% in the second quarter. Principal Financial Group Inc. now owns 124,174 shares of the company’s stock worth $4,125,000 after purchasing an additional 21,658 shares in the last quarter. Teachers Advisors LLC grew its stake in shares of Teva Pharmaceutical Industries by 6.3% in the second quarter. Teachers Advisors LLC now owns 682,914 shares of the company’s stock worth $22,686,000 after purchasing an additional 40,600 shares in the last quarter. Finally, TIAA CREF Investment Management LLC grew its stake in shares of Teva Pharmaceutical Industries by 5.4% in the second quarter. TIAA CREF Investment Management LLC now owns 666,074 shares of the company’s stock worth $22,127,000 after purchasing an additional 33,938 shares in the last quarter. 51.93% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/12/btig-research-lowers-teva-pharmaceutical-industries-teva-to-neutral.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply